Working through two subsidiaries, life sciences giant Bayer is taking multiple shots at Parkinson’s disease. In addition to Bayer’s efforts to tackle Parkinson’s, Adhera Therapeutics announced that the company will acquire a new class of drug aimed at the disease.

Johnson & Johnson decided to terminate a $1.6 billion partnership with Argenx to develop the anti-CD70 antibody cusatuzumab to treat amyotrophic lateral sclerosis (AML) and myelodysplastic syndromes (MDS).

Now, a few years down the road,

Fishawack Health, a leading global commercialization partner for the life sciences industry, announced the acquisition of Chicago-based closerlook LLC. closerlook is a digital-native healthcare agency that leverages artificial intelligence (AI) and data analytics to develop omnichannel strategies, creative and digital media solutions for life science brands across the entire pre-commercial and commercial lifecycle of a drug.

Following huge success over the past 3.5 years, the allegro. accelerated learning and development model is adding a new program to its portfolio. The launch of allegro.EXCEL provides structured career development for senior medical writers to accelerate their career to scientific leadership positions in Ashfield Health.

United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.

U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.

AstraZeneca

British life sciences company NetScientific Plc said on June 7 that one of the company’s subsidiaries entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a Covid-19 test.

Bayer announced an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. in an effort to expand the global biopharmaceutical company’s portfolio of targeted alpha radionuclide therapies for prostate cancer.

AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on June 3.

Ashfield Engage, part of UDG Healthcare plc, today announced that it has been selected by U.S.-based Pacira BioSciences Inc. to provide strategic commercialization services for the company’s non-opioid pain management products in select European countries. Pacira has partnered with Ashfield Engage to develop a commercial strategy and deliver outsourced operations in numerous European countries, including the UK, Germany, Sweden, Austria, the Netherlands and Finland.